Merck Gets Positive EU CHMP Opinion for WELIREG Plus Lenvatinib
The CHMP backed WELIREG (belzutifan) with lenvatinib for adults with advanced clear-cell renal cell carcinoma after prior treatment.
The CHMP backed WELIREG (belzutifan) with lenvatinib for adults with advanced clear-cell renal cell carcinoma after prior treatment.